09/888,326 Art Unit 1635

which includes these two SEQ ID NOs. Applicants believe the substitute Sequence Listing satisfies the requirements of 37 C.F.R. §§ 1.821-1.825. No new matter has been added.

Group I is elected for examination, with traverse.

Respectfully submitted,

Alan W. Steele, Reg. No. 45,128

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, MA 02210-2211

(617) 720-3500

Docket No. C01039.70052.US

Date: October 10, 2002

x10/23/02

Art Unit 1635



## Addendum to Amendment and Election, Showing Nature of Amendments to the Specification

At page 9, lines 8-13:

In some embodiments the poly-G nucleic acid comprises: 5' X<sub>1</sub>X<sub>2</sub>GGGX<sub>3</sub>X<sub>4</sub> 3' wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> are nucleotides. In embodiments at least one of X<sub>3</sub> and X<sub>4</sub> are a G or both of X<sub>3</sub> and X<sub>4</sub> are a G. In other embodiments the poly-G nucleic acid comprises the following formula: 5' GGGNGGG 3' wherein N represents between 0 and 20 nucleotides. In yet other embodiments the poly-G nucleic acid comprises the following formula: 5' GGGNGGGG 3' (SEQ ID NO:849) wherein N represents between 0 and 20 nucleotides.

At page 39, lines 10-19:

In some embodiments N<sub>1</sub> and N<sub>2</sub> of the nucleic acid do not contain a CCGG or CGCG quadmer or more than one CCG or CGG trimer. The effect of a CCGG or CGCG quadmer or more than one CCG or CGG trimer depends in part on the status of the nucleic acid backbone. For instance, if the nucleic acid has a phosphodiester backbone or a chimeric backbone the inclusion of these sequences in the nucleic acid will only have minimal if any affect on the biological activity of the nucleic acid. If the backbone is completely phosphorothioate or significantly phosphorothioate then the inclusion of these sequences may have more influence on the biological activity or the kinetics of the biological activity, but compounds containing these sequences are still useful. In another embodiment the CpG nucleic acid has the sequence 5' TCN<sub>1</sub>TX<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>4</sub> 3' (SEQ ID NO:850).

At page 40, line 25 – page 41, line 7:

Poly G nucleic acids preferably are nucleic acids having the following formulas:

## 5' X<sub>1</sub>X<sub>2</sub>GGGX<sub>3</sub>X<sub>4</sub> 3'

wherein  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  are nucleotides. In preferred embodiments at least one of  $X_3$  and  $X_4$  are a G. In other embodiments both of  $X_3$  and  $X_4$  are a G. In yet other embodiments the preferred formula is 5' GGGNGGG 3', or 5' GGGNGGGNGGG 3' (SEQ ID NO:849) wherein N represents between 0 and 20 nucleotides. In other embodiments the poly-G nucleic acid is free of unmethylated CG dinucleotides, such as, for example, the nucleic acids listed in Table 4 below as SEQ ID NOs: 12-14, 23, 56, 100, 155, 163, 182, 227, 237, 246, 400, 407, 429, 430, 432, 435, 438, 439, 446, 450, 451, 480, 487, 493, 522, 661, 662, 671-673, 807, 808, 821, 823, and 834. In other embodiments the poly-G nucleic acid includes at least one unmethylated CG dinucleotide, such as, for example, the nucleic acids listed in Table 4 below as SEQ ID NOs: 6, 7, 22, 26, 28-30, 87, 115, 141, 177, 191, 209, 254, 258, 267, 303, 317, 329, 335, 344, 345, 395, 414, 417, 418, 423-426, 428, 431, 433, 434, 436, 437, 440, 442-445, 447-449, 458, 460, 463, 467-469, 474, 515, 516, 594, 638-640, 663, 664, 727, 752, 776, 795, 799, 817, 818, 831, and 832.